Improving Immunotherapy Research Workflows using Creative Biolabs' Biological Products

Creative Biolabs launched a wide range of ready-to-use aptamers and macrophage cell lines for speeding up research discoveries.
New York, USA - November 19, 2025 - To advance immunological studies and drug discovery, Creative Biolabs, a world leader in custom biotechnology solutions, is pleased to announce that ready-to-use aptamers [https://www.creative-biolabs.com/complement-therapeutics/category-aptamers-359.htm] as well as macrophage cell lines from different species and sources are now available.

Image: https://www.getnews.info/uploads/0c59d26f78bf6dd58aafee5bc68d7d8c.jpg

Along with a comprehensive collection of macrophage cell lines derived from human, murine, canine, and non-human primate sources, this strategic expansion comprises a carefully chosen set of high-affinity aptamers that target important immunological markers. These products provide researchers previously unheard-of flexibility and dependability across preclinical workflows, and were created to satisfy the increasing demand for translational and immunology models.

"We are proud to provide scientists with the tools they need to delve into immune mechanisms in a highly controlled and repeatable way," said the director of cell biology at Creative Biolabs. "Our ready-to-use aptamers and macrophage cell lines [https://macrophage.creative-biolabs.com/category-macrophages-881.htm] are optimized for immediate integration into experimental pipelines, minimizing setup time while maximizing data quality."

Creative Biolabs also provides aptamers specific to proteins, peptides, small molecules, and even cells or viruses. "Our anti-botulinum toxin type A aptamer is used in biosensors designed to detect the presence of botulinum toxin," said a scientist.

Creative Biolabs has macrophage cell lines from both primary and immortalized sources, with M0, M1, and M2 phenotypes. The macrophage cell lines fit nicely with the aptamer suite. "We provide detailed characterization of each of the lines, including surface marker expression, cytokine profiles, and responses to stimuli such as LPS, IFN-, and IL-4." said the scientist.

This company provides a range of high-quality cell products [https://neuros.creative-biolabs.com/category-neural-cell-lines-42.htm] to support neural cell-based assays in neuroscience research and drug discovery, including but not limited to central and peripheral nerve cells from different species. The cell products are produced using quality control procedures which support batch-to-batch consistency, endotoxin free purity, and functional integrity.

"To facilitate immunology research, we are focused on the development of integrated, species-diverse solutions that reduce experimental variability and increase discovery pace," a senior scientist stated. "Our platform is designed to best assist your science, whether that be examining how macrophages drive inflammation, how tumor microenvironments alter, or how vaccines function."

Creative Biolabs' newest products are in line with its larger goal of connecting basic research with medicinal development using biological instruments that can be customized, scaled, and obtained responsibly. The company continues to invest in expanding its cell-based platforms.

To explore the full catalog or request custom solutions, please visit https://www.creative-biolabs.com/complement-therapeutics.

About Creative Biolabs

Creative Biolabs is a biotechnology company based in the USA that provides a wide variety of biological products, such as aptamers, macrophages and cell lines, to speed up scientific research and support innovative project development for all life science disciplines.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email [http://www.universalpressrelease.com/?pr=improving-immunotherapy-research-workflows-using-creative-biolabs-biological-products]
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/complement-therapeutics

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.